Wire · regulatory
CHMP recommends EU approval of belzutifan plus lenvatinib for advanced ccRCC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 November 2026 · Fusion42 review
The European Medicines Agency’s CHMP has recommended approval of belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma (ccRCC) after PD-(L)1 inhibitor therapy, supported by phase 3 trial data showing improved progression-free survival versus cabozantinib. The decision will proceed to the European Commission with a final decision expected within two months, positioning this combination as a new treatment option across the EU/EEA.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a timely path to market access for belzutifan plus lenvatinib in Europe, opening a significant post-PD-(L)1 ccRCC treatment niche. Prioritise engagement with EU payers and oncology networks to prepare for rapid uptake after formal approval.
◆ Coverage
1 source · 13 Nov 2026
◆ Related on Wire
◆ Topics